Drews Steven J, Devine Dana V, McManus Janet, Mendoza Emelissa, Manguiat Kathy, Wood Heidi, Girardin Roxie, Dupuis Alan, McDonough Kathleen, Drebot Michael
Microbiology, Canadian Blood Services, Edmonton, Alberta, Canada.
Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada.
Transfusion. 2021 May;61(5):1440-1446. doi: 10.1111/trf.16364. Epub 2021 Mar 18.
Convalescent plasma products are a potential passive immunotherapy for Coronavirus disease 2019 (COVID-19) disease. Various approaches have been utilized to determine the concentration of Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)-neutralizing antibodies in plasma products. The Canadian Blood Services used Plaque Reduction Neutralization Test 50 (PRNT -generated values to qualify convalescent plasma donations supporting clinical trials in Canada. This manuscript describes changes in PRNT titers of repeat male plasma donations collected approximately 1-4 months after onset of COVID-19 signs and symptoms in donors.
Men were eligible to donate if they: met standard criteria, were < 67 years of age, reported a previous SARS-CoV-2-positive nucleic acid test, and recovered and were symptom free for at least 28 days prior to donation. Repeat donation analysis required at least one original and one repeat donation where a PRNT was performed.
From April 29, 2020 to July 25, 2020, 156 donors donated once, with 78 (50%) of the donated plasma having PRNT titers of ≥1:160. Thirty-seven (23.7%) of the donated plasma had a titer of 1:40 or 1:80 (individuals donating this plasma were asked to donate a second time only). A total of 30 donors (19.2%) had repeat donations. Of the repeat donors, 15 (50%) had at least an eightfold change from peak to trough PRNT titers within greater than 90 days after onset of COVID-19 symptoms.
Blood operators cannot infer that SARS-CoV-2 PRNT will remain high in repeat plasma donors 3-4 months after onset of COVID-19 symptoms.
恢复期血浆制品是治疗2019冠状病毒病（COVID-19）的一种潜在被动免疫疗法。已采用各种方法来测定血浆制品中严重急性呼吸综合征冠状病毒2（SARS-CoV-2）中和抗体的浓度。加拿大血液服务中心使用空斑减少中和试验50（PRNT-50）生成的值来鉴定支持加拿大临床试验的恢复期血浆捐献。本文描述了在捐献者出现COVID-19体征和症状后约1-4个月采集的男性重复血浆捐献的PRNT滴度变化。
符合以下条件的男性有资格捐献：符合标准标准，年龄<67岁，报告既往SARS-CoV-2核酸检测呈阳性，康复且在捐献前至少28天无症状。重复捐献分析要求至少有一次进行了PRNT的原始捐献和一次重复捐献。
2020年4月29日至2020年7月25日，156名捐献者捐献了一次，其中78份（50%）捐献的血浆PRNT滴度≥1:160。37份（23.7%）捐献的血浆滴度为1:40或1:80（捐献该血浆的个体仅被要求再次捐献）。共有30名捐献者（19.2%）进行了重复捐献。在重复捐献者中，15名（50%）在COVID-19症状出现后90多天内，PRNT滴度从峰值到谷值至少有8倍的变化。
血液采集机构不能推断COVID-19症状出现后3-4个月重复血浆捐献者的SARS-CoV-2 PRNT会一直保持在高位。
